The increasing interest in potent weight management has led to considerable exploration into novel treatments. Recently , Retatrutide, a combined -action GIP and glucagon-like peptide-1 (GLP-1) receptor agonist , has exhibited promising results in medical trials, implying potential for significant weight decrease. As a result , many individuals are